Department of Chemistry, Graduate School of Science , The University of Tokyo , 7-3-1 Hongo , Bunkyo-ku, Tokyo 113-0033 , Japan.
J Am Chem Soc. 2019 Mar 13;141(10):4167-4181. doi: 10.1021/jacs.8b13178. Epub 2019 Feb 27.
Peptides as a therapeutic modality attract much attention due to their synthetic accessibility, high degree of specific binding, and the ability to target protein surfaces traditionally considered "undruggable". Unfortunately, at the same time, other pharmacological properties of a generic peptide, such as metabolic stability and cell permeability, are quite poor, which limits the success of de novo discovered biologically active peptides as drug candidates. Here, we review how macrocyclization as well as the incorporation of nonproteogenic amino acids and various conjugation strategies may be utilized to improve on these characteristics to create better drug candidates. We analyze recent progress and remaining challenges in improving individual pharmacological properties of bioactive peptides, and offer our opinion on interfacing these, often conflicting, considerations, to create balanced drug candidates as a potential way to make further progress in this area.
由于肽类具有合成可及性、高度特异性结合以及靶向传统上认为“不可成药”的蛋白质表面的能力,因此作为一种治疗方式引起了广泛关注。不幸的是,与此同时,通用肽的其他药理学特性,如代谢稳定性和细胞通透性,相当差,这限制了新发现的具有生物活性的肽作为候选药物的成功。在这里,我们回顾了环化以及非天然氨基酸的掺入和各种缀合策略的应用如何改善这些特性,以创造更好的候选药物。我们分析了改善生物活性肽的个别药理学特性方面的最新进展和仍然存在的挑战,并就如何处理这些经常相互冲突的考虑因素提出了看法,以创建平衡的候选药物,作为在该领域取得进一步进展的一种潜在途径。